By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ovid Therapeutics 

1460 Broadway Street

New York  New York   10036  U.S.A.
Phone: 646-661-7661 Fax: n/a


Key Statistics

Ownership: Public

Web Site: Ovid
Symbol: OVID


Company News
Ovid (OVID) Appoints Ana C. Ward As Senior Vice President And General Counsel 9/6/2017 10:12:33 AM
CEOs Of Decibel And Ovid (OVID) Urge Peers To 'Stand Up To Trump' 8/24/2017 6:47:49 AM
Ovid (OVID) Reports Second Quarter 2017 Financial Results And Corporate Progress 8/11/2017 11:07:18 AM
Ovid (OVID) To Be Added To Russell 2000, 3000 And Microcap Indexes 6/23/2017 8:12:28 AM
New York's Ovid (OVID) Raises $75 Million In IPO Debut 5/5/2017 7:20:32 AM
It's Official: Ovid CEO Just Filed for $86 Million IPO 4/12/2017 6:22:59 AM
Ovid Announces Initiation Of Phase I Clinical Trial Of OV101 For Adolescents With Angelman Syndrome Or Fragile X Syndrome 4/10/2017 10:54:43 AM
Ovid And NeuroPointDx Announce Collaboration To Identify Biomarkers For Angelman Syndrome 2/9/2017 6:36:16 AM
Ovid Release: Company Names Jacqueline A. French, M.D., To Scientific Advisory Board 1/20/2017 10:07:58 AM
Tiny Ovid Inks a Unique Rare Disease Deal With Drug Giant Takeda (TKPYY) 1/18/2017 5:39:12 AM